Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > VRTX > Summary

Vertex Pharmaceuticals Incorporated
(VRTX)

37.90USD   Up0.48 (1.28%)   
At 2:30AM IST
 Vertex Pharmaceuticals Incorporated (NasdaqNM:VRTX) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 37.90USD
Trade Time:2:30AM IST
Change:Up0.48 (1.28%)
Prev Close:37.42
Open:37.78
Bid:N/A
Ask:43.10 x 1200
1y Target Est:42.94
Day's Range:37.33 - 38.36
52wk Range:25.94 - 44.24
Volume:1,208,365
Avg Vol (3m):2,008,970
Market Cap:6.87B
P/E (ttm):N/A
EPS (ttm):-3.82
Div & Yield:N/A (N/A%)
Add VRTX to Portfolio   Download Data

HEADLINES

 
•New Star Analyst Rankings for Vertex Pharmaceuticals Incorpor - StarMine  - Sat, Feb 6
•Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcript - Seeking Alpha  - Fri, Feb 5
•[video] Successfactors, Pitney Bowes Announce - Forbes.com  - Fri, Feb 5
•UPDATE - Vertex 4th quarter loss grows with costs - Reuters  - Fri, Feb 5
•VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen - EDGAR Online  - Fri, Feb 5
•Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs - Business Wire  - Fri, Feb 5
•Full Year 2009 Vertex Pharmaceuticals Incorporated Earnings Release - After Market Close - CCBN  - Thu, Feb 4
•Vertex sees positive data in cystic fibrosis study - AP  - Wed, Feb 3
•UPDATE - Vertex cystic fibrosis drug shows promise in trial - Reuters  - Wed, Feb 3
•Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis - Business Wire  - Wed, Feb 3
» More Headlines for VRTX...

ANALYST

 
EPS Est (next year) (Dec-09) :-3.70
EPS Est (in 2 years) (Dec-10) :-3.12
Avg Rec (current)*:2.1
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.

» Full Company Profile